Investigating a new treatment for cancers with DNA repair defects
Official title: Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer
Funded at Yale University · NIH-10932120 · Data updated 2026-11-12
This study is testing a new treatment called KL-50 for certain cancers that have trouble fixing their DNA, especially those related to the MGMT gene, and it aims to help patients with cancers like gliomas and colon cancer by making the tumors more vulnerable to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 20, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $418,750 |
| NIH project number | 5DP5OD036128-02 |
| Project ID | NIH-10932120 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers characterized by MGMT silencing and DNA repair deficiencies, such as glioblastomas and colon cancer.
✕Less likely to help
Patients with cancers that do not exhibit MGMT silencing or significant DNA repair defects may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for cancers that have specific defects in DNA repair mechanisms, particularly those involving the MGMT gene. The approach involves using a new agent, KL-50, which creates DNA damage specifically in tumor cells lacking MGMT, thereby bypassing resistance mechanisms seen with traditional treatments like temozolomide. By targeting these vulnerabilities, the research aims to improve treatment outcomes for patients with various types of cancer, including gliomas and colon cancer. Patients may be involved in clinical trials to assess the effectiveness and safety of this new therapeutic agent.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with DNA repair deficient cancers.
How similar studies have gone: Other research has shown promise in targeting DNA repair deficiencies in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Gueble, Susan E — Yale University
- Study coordinator: Gueble, Susan E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.